ArticleJournal of global health2026
Resilience to HPV vaccine safety scares in seven countries.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Resilience is the ability of a vaccination programme to return to high coverage after a disrupting event, such as a safety scare that undermines vaccine provision. To identify insights that can help countries achieve resilience in their vaccination programmes, we reviewed the experiences of countries that faced HPV vaccine safety scares. Methods: We developed case studies on HPV vaccine safety scares in three high-income (Denmark, Ireland, and Japan) and four middle-income countries (Brazil, Colombia, India, and Mongolia). The case studies included information on the safety scare, subsequent response, and impact on HPV vaccine uptake. Results: Reports of unfounded HPV vaccine safety concerns were amplified through traditional broadcast media coverage and perpetuated by parent groups and political leaders. After safety scares, five countries had widespread decreases in HPV vaccine coverage, one had regional drops in coverage, and two suspended introductions of the vaccine. Countries' strategies varied, but typically involved coalitions of government entities, healthcare providers, community leaders, and cancer prevention organisations. All the countries were able to increase their HPV vaccine coverage or restart vaccine introduction. Conclusions: Safety scares were often imported from other countries, gained momentum through traditional media coverage, and were abetted by political leaders, delays by some vaccination programmes, and the absence of effective crisis communication plans. To build resilient HPV vaccination programmes, leaders should respond quickly to safety scares, develop a broad coalition (providers, political and community), share credible messages that emphasise cancer prevention, and communicate across traditional and social media.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.